Vanderbilt-Ingram Cancer Center

Eng named co-chair of NCI clinical trials steering committee

Vanderbilt’s Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.

Structural variants in breast cancer risk genes

Vanderbilt epidemiologists conducted in-depth whole genome sequencing of breast cancer risk genes in Black women, who die at higher rates and have more aggressive disease, to discover mutations that may improve testing and treatment selection.

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.

The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.

Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).

1 14 15 16 17 18 26